Results 11 to 20 of 158 matches
Category 6 - PATHOLOGY SERVICES
73298 - Additional Information
Characterisation of germline gene variants in the following genes:
(a) COL4A3; and
(b) COL4A4; and
(c) COL4A5;
in a patient for whom clinical and relevant family history criteria have been assessed by a specialist or consultant physician, who requests the service to be strongly suggestive of Alport syndrome.
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30
Category 6 - PATHOLOGY SERVICES
73299 - Additional Information
Characterisation of germline gene variants:
(a) in the following genes:
(i) COL4A3; and
(ii) COL4A4; and
(iii) COL4A5;
(b) in a patient who:
(i) is a first degree biological relative of a patient who has had a pathogenic mutation identified in one or more of the genes mentioned in subparagraphs (a)(i), (ii) and (iii); and
(ii) has not previously received a service which item 73298 applies;
requested by a specialist or consultant physician.
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
Category 6 - PATHOLOGY SERVICES
73300 - Additional Information
Detection of mutation of the FMR1 gene where:
(a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMRI mutation; or
(b) the patient has a relative with a FMR1 mutation
1 or more tests
Fee: $101.30 Benefit: 75% = $76.00 85% = $86.15
(See para PN.0.23, PN.7.16 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73301 - Additional Information
A test of tumour tissue from a patient with advanced (FIGO III-IV), high grade serous or high grade epithelial ovarian, fallopian tube or primary peritoneal cancer, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor under the Pharmaceutical Benefits Scheme (PBS)
Applicable once per primary tumour diagnosis
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30
Category 6 - PATHOLOGY SERVICES
73302 - Additional Information
Characterisation of germline gene variants including copy number variants, in BRCA1 or BRCA2 genes, in a patient who has had a pathogenic or likely pathogenic variant identified in either gene by tumour testing and who has not previously received a service to which items 73295, 73296 or 73297 applies, requested by a specialist or consultant physician.
Applicable once per primary tumour diagnosis
Fee: $400.00 Benefit: 75% = $300.00 85% = $340.00
Category 6 - PATHOLOGY SERVICES
73303 - Additional Information
A test of tumour tissue from a patient with metastatic castration-resistant prostate cancer, including subsequent characterisation of germline gene variants should tumour tissue testing undertaken during the same service be inconclusive, requested by a specialist or consultant physician, to determine eligibility relating to BRCA status for access to olaparib under the Pharmaceutical Benefits Scheme.
Applicable once per primary tumour diagnosis
Fee: $1,000.00 Benefit: 75% = $750.00 85% = $901.30
Category 6 - PATHOLOGY SERVICES
73304 - Additional Information
Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, in a patient with metastatic castration‑resistant prostate cancer, for whom testing of tumour tissue is not clinically feasible, requested by a specialist or consultant physician, to determine eligibility for olaparib under the Pharmaceutical Benefits Scheme.
Applicable once per lifetime
Fee: $1,000.00 Benefit: 75% = $750.00 85% = $901.30
(See para PN.0.23 of explanatory notes to this Category)
Category 6 - PATHOLOGY SERVICES
73305 - Additional Information
Category 6 - PATHOLOGY SERVICES
73306 - Additional Information
Gene expression profiling testing using EndoPredict, for the purpose of profiling gene expression in formalin‑fixed, paraffin‑embedded primary breast cancer tissue from core needle biopsy or surgical tumour sample to estimate the risk of distant recurrence of breast cancer within 10 years, if:
(a) the sample is from a new primary breast cancer, which is suitable for adjuvant chemotherapy; and
(b) the sample has been determined to be oestrogen receptor positive and HER2 negative by IHC and ISH respectively on surgically removed tumour; and
(c) the sample is axillary node negative or positive (up to 3 nodes) with a tumour size of at least 1 cm and no more than 5 cm determined by histopathology on surgically removed tumour; and
(d) the sample has no evidence of distal metastasis; and
(e) pre‑testing of intermediate risk of distant metastases has shown that the tumour is defined by at least one of the following characteristics:
(i) histopathological grade 2 or 3;
(ii) one to 3 lymph nodes involved in metastatic disease (including micrometastases but not isolated tumour cells); and
(f) the service is not administered for the purpose of altering treatment decisions
Applicable once per new primary breast cancer diagnosis for any particular patient
Fee: $1,200.00 Benefit: 75% = $900.00 85% = $1,101.30
Category 6 - PATHOLOGY SERVICES
73307 - Additional Information
A test of tumour tissue from a patient with advanced (FIGO III-IV), high-grade serous or other high-grade ovarian, fallopian tube or primary peritoneal carcinoma, requested by a specialist or consultant physician, if the test is:
(a) to determine eligibility with respect to homologous recombination deficiency (HRD) status, including BRCA1 or BRCA2 status, to provide access to poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapy under the Pharmaceutical Benefits Scheme; and
(b) including a service described in item 73301
Applicable once per primary tumour diagnosis
Fee: $3,000.00 Benefit: 75% = $2,250.00 85% = $2,901.30
Results 11 to 20 of 158 matches
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change